SAVARA INC (SVRA)
US8051111016 - Common Stock
Overall SVRA gets a fundamental rating of 2 out of 10. We evaluated SVRA against 565 industry peers in the Biotechnology industry. SVRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SVRA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year SVRA has reported negative net income.
SVRA had a negative operating cash flow in the past year.
SVRA had negative earnings in each of the past 5 years.
SVRA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of SVRA (-53.90%) is comparable to the rest of the industry.
SVRA has a Return On Equity (-74.01%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.9% | ||
| ROE | -74.01% | ||
| ROIC | N/A |
ROA(3y)-27.48%
ROA(5y)-38.13%
ROE(3y)-34.71%
ROE(5y)-51.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SVRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SVRA has been increased compared to 1 year ago.
Compared to 5 years ago, SVRA has more shares outstanding
SVRA has a better debt/assets ratio than last year.
2.2 Solvency
SVRA has an Altman-Z score of 2.86. This is not the best score and indicates that SVRA is in the grey zone with still only limited risk for bankruptcy at the moment.
SVRA has a better Altman-Z score (2.86) than 75.04% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that SVRA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.26, SVRA is not doing good in the industry: 69.34% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.86 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
SVRA has a Current Ratio of 11.31. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of SVRA (11.31) is better than 84.49% of its industry peers.
A Quick Ratio of 11.31 indicates that SVRA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 11.31, SVRA belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.31 | ||
| Quick Ratio | 11.31 |
3. Growth
3.1 Past
The earnings per share for SVRA have decreased strongly by -50.00% in the last year.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
SVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.72% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.55%
EPS Next 2Y-15.06%
EPS Next 3Y2.71%
EPS Next 5Y26.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SVRA. In the last year negative earnings were reported.
Also next year SVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.06%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
SVRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SAVARA INC
NASDAQ:SVRA (11/20/2024, 8:00:00 PM)
Premarket: 3.18 +0.05 (+1.6%)3.13
+0.19 (+6.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap515.20M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.9% | ||
| ROE | -74.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 11.31 | ||
| Quick Ratio | 11.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-37.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y